Breaking News

0 320
CombiMatrix Corp CBMX Stock News

CombiMatrix Corp (NASDAQ: CBMX)

CombiMatrix is having a great time in pre-market trading at the moment, and for good reason. Yesterday, after the closing bell, the company released its earnings report. Below, we’ll talk about what we saw from the earnings report, what we’re seeing from the stock as a result, and what binary options traders should be watching for ahead.





What We Saw From The CBMX Report

As mentioned above, CombiMatrix reported its earnings after the closing bell yesterday, beating expectations. Here’s what we saw from the report…

  • Earnings Per Share – In terms of earnings per share, CBMX did overwhelmingly well. In fact, during the quarter, analysts expected that the company would generate a loss of $0.39 per share. However, the company actually reported a loss of $0.22 per share, blowing away expectations.
  • Revenue – When it comes to revenue, investors received more good news. During the quarter, analysts expected that the company would generate revenue in the amount of $2.68 million. However, the company actually reported revenue for the quarter in the amount of $3.54 million.




How The Stock Reacted To The News

As is always the case, earnings move the market. In this case, this is no different. The strong earnings are leading to strong gains on the stock. Currently (9:20), CBMX is trading at $4.85 per share after a gain of $0.80 per share or 19.75% thus far today.

What We’ll Be Watching For Ahead

Moving forward, the CNA Finance team will be keeping a close eye on CBMX. In particular, we’re interested in the company’s progress with regard to its impressive pipeline. Nonetheless, we’ll be watching the stock closely and bringing all news to you as it breaks!

Never Miss The News Again

Do you want real-time, actionable news delivered to your inbox? Join the CNA Finance mailing list below!

Subscribe Today!

* indicates required










0 2074
Pernix Therapeutics Holdings Inc PTX Stock News

Pernix Therapeutics Holdings Inc (NASDAQ: PTX)

Finally, PTX shareholders have come into some positive news, a welcome filing that can help erase the long time frowns that have been etched onto the faces of longtime PTX holders, myself included.

Not only do the markets work in mysterious ways, the court system does as well. Still reeling from PTX”s most recent legal setback regrading its marketing rights for drugs just over a week ago, the U.S. District Court in Delaware provided a ray of sunshine, and the effects can have a far reaching and lasting effect for PTX shareholders.





Pernix Gets A Break And Value

For smarties like me, there was never any doubt that the ‘096 and ‘742 patents were being infringed. It was just plain obvious, and why it took hundreds of thousands of dollars to litigate beats the little bit of sense out of me. I was only a phone call away and could have settled this case months ago for a #4 Double Quarter Pounder meal at McD’s.

Seriously, Pernix, as the licensee, had the goods in the bag, clearly distinguishing its proprietary value in Zohydro ER, proving it was distinct in both technology and abuse deterrent compound, as well as in mechanism. The patents in question involved the abuse deterrent compounds and it mechanism to inhibit potential abuse. Both the ‘742 and ‘096 patents are well written, with original claims dating back to 1998 for ‘742 and 2015 for ‘096. The patents are protected until 2019 and 2034, receptively. The active ingredient is hydrocodone bitartrate, part of a widely abused family of pain killing drugs. The real case, though, was about the the technology and abuse deterrent compounds that surround that hydrocodone, making that good stuff hard to get to if the patient does not follow proper dosing instructions..




As with all court decisions, the decision is lengthy and somewhat confusing at times, and while the court makes reference to parts of the whole not necessarily being infringed, the sum of the parts, stated by the court read as , “having considered the entire case, the substantial evidence in the record, the parties post-trial submissions, and the applicable law, the court concludes that Activis’ proposed products infringe the asserted claims of the ‘096, but do not infringe the asserted claims of the ‘742 patents”. HOWEVER, because no ruling can be quite so simple, parts of the ‘742 stand, causing the court to publish the following remedy, “…..Under 35 U.S.C. 271(e)(4)(A), the effective date of any FDA approval of Activis’ ANDA No. 20-6952 shall be a date not earlier than the later expiration date of the ‘096 and ‘742 patents, including any extensions and marketing exclusivities (September 2034)

(Civil Action No. 14-1118-GMS)

Court Decision

In a nutshell, Actavis, its officers, agents, employees, et al, shall be enjoined from engaging in the commercial manufacture, use, offer to sell, or sale with the United States, or importation into the United States of Activis’ ANDA product prior to the expiration of the ‘096 and ‘742 patents.

So, as PTX shareholders, perhaps we may rejoice for a day or two, and even enjoy a possible new trend higher, one that drives the price high enough to attract hungry pharmaceutical investors to bid the stock to a potential buyout at double digit levels, instead of the “Lincoln” that many of us fear.

But, one step at a time. While this is a great victory, and a much needed breath of fresh air, PTX still has some work to do. It’s time for management to harness the value within this decision, and make the company real pretty, with shiny bells and whistles. From there, maybe they can consider packaging the company for sale to an interested party that is willing to pay fair value for PTX. Fair value for most is the price they paid, assuming an investment was made prior to six months ago. I’ll take the highest fair value available, by the way.

As long as the respirator is removed, shareholders stand a solid chance of PTX regaining its footing and marching forward into greener pastures. The drugs under management are strong, and with this issue no longer hanging over their head, shareholders hold hope that better times are ahead.

Disclosure: This article was written by Kenny Soulstring, and it reflects my own opinions and unique articulation. This article is not intended to offer investing advice, guarantee 100% accurate predictions or to be interpreted as providing a personal recommendation. What I can guarantee, though, is accurate research, thoughtful analysis and an enthusiasm about any stock that I cover.

While I seek to uncover emerging companies that I feel have true value and potential, it’s important that investors assign an appropriate time horizon to each of their investments, understanding that emerging companies need time to mature.

I wrote this article myself and it includes my own research and expresses my own opinions. I am not receiving compensation for it (other than from CNA Finance). I have no business relationship with any company whose stock is mentioned in this article.

Additional Disclosure: I have no position in any stock mentioned, but may initiate a long position in PTX within the next 72 hours.

Update Feb 23, 11:14 EST – PTX is having a great day following yesterday’s news. While the stock is seeing some ups and some downs, strong gains seem to be here to stay. At the moment, the stock is trading at $3.92 per share after a gain of $1.18 per share or 43.06% thus far today.

Never Miss The News Again

Do you want real-time, actionable news delivered to your inbox? Join the CNA Finance mailing list below!

Subscribe Today!

* indicates required










0 640
Cree, Inc. CREE Stock News

Cree, Inc. (NASDAQ: CREE)

Cree is having an incredibly interesting day in the market today. At the opening bell, the stock was trading in the red. As soon as trading started, the stock quickly pushed to the green before falling back to the red and remained relatively flat throughout the morning. However, minutes ago, that all changed as the stock started to run for the top. Below, we’ll talk about what we’re seeing from CREE, why, and what we’ll be watching for ahead.





What We’re Seeing From CREE

As mentioned above, CREE is having an interesting day in the market, to say the least. At the open of the market, the stock was trading in the red before spiking to the green. That didn’t last, however, as the stock spiked back down right to where it was. Throughout the morning, we saw some movement, but the stock remained red. That is, until minutes ago when it started to spike toward the top. At the moment (11:28), CREE is trading at $27.36 per share after a gain of $0.22 per share (0.79%) thus far today.

Why The Stock Is Spiking Upward

As is usually the case, our friends at Trade Ideas were the first to inform us of the gains on CREE. As soon as we received the alert, the CNA Finance team started digging to see if we could dig up the cause of the gains. It didn’t take long to dig up. While there has been no fundamental news released by the company that would lead to such gains, there is a rumor surfacing.




At the moment, all over social media, we’re seeing a rumor surrounding Cree. That rumor is that there is a private equity group that is interested in acquiring a large part of – or all of – the company. The rumor doesn’t offer any details with regard to who the private equity group is, how much of the company they wish to buy, nor the price per share at which they are going to make an offer.

What We’ll Be Watching For Ahead

Moving forward, the CNA Finance team will be keeping an incredibly close eye on CREE. In particular, we’re watching to see if there is any validity to the rumor. Considering that there has been no confirmation from Cree and the rumor is very vague, chances are that it’s not going to happen. However, we could be wrong. We’ll continue to follow the story and bring it to you as it breaks!

Update (12:46): CREE just made another spike upward and is continuing to make a run. The stock is currently trading at $27.71 per share after a gain of $0.57 per share (2.11%) thus far today. The most recent spike seems to be correlated with a mention of the stock by CNBC’s Pete Najarian. We’ll continue to follow the story and bring you the news as it breaks!

Never Miss The News Again

Do you want real-time, actionable news delivered to your inbox? Join the CNA Finance mailing list below!

Subscribe Today!

* indicates required










DryShips Inc. DRYS Stock News

DryShips Inc. (NASDAQ: DRYS)

DryShips is having a very bad day in the market today, only falling further after yesterday’s declines. While the stock was trading in the green at the open, that didn’t last very long. As soon as the trading session started, the stock started to dive, quickly making it to the red and beyond. Below, we’ll talk about what we’re seeing from DRYS, why, and what we’ll be watching for ahead.





What We’re Seeing From DRYS

As mentioned above, DryShips isn’t having the best of days in the market today. In fact, the stock is seeing some big losses. In the pre-market, things looked like they might go well. In fact, the stock opened the day slightly in the green, thanks to strong pre-market activity. Nonetheless, at the open, it took a dive, and it has been falling ever since. At the moment (11:08), DRYS is trading at $2.75 per share after a loss of $0.53 per share (16.16%) thus far today.

Why The Stock Is Falling

As is almost always the case, our partners at Trade Ideas brought the alert to us first about the downward movement on DRYS. As soon as we received the alert, the CNA Finance team started working to see why the stock was falling so hard. The truth is that there has been no fundamental news released that would suggest such strong declines. Nonetheless, we believe we know the reason for the fall.




A short while ago, DryShips announced a $200 million fund raise. While most experts covering the story saw it as incredibly dillutive and not likely to be in the best interest of investors, excitement surrounding the raise sent the stock higher. However, that excitement has died off, and now investors are back to concerns.

At the end of the day, DRYS isn’t in the best position at the moment. Not only is the company likely to hit some major financial headwinds soon, there are also allegations of potential fraud on behalf of the CEO that have been surfacing for weeks. With no new positive news, investors are forced to move based on what they know about the company; unfortunately, that’s not good news for the stock price.

What We’ll Be Watching For Ahead

Moving forward, the CNA Finance team will be keeping a close eye on DRYS. In particular, we’re watching for an update from the company in an attempt to stop the bleeding. We’ll keep a close eye on the news and continue to bring it to you as it breaks!

Update (11:43): DRYS continues on the steady downtrend. Currently, the stock is trading at $2.68 per share after a loss of $0.60 per share (18.45%) thus far today. Considering the rate of the fall, it wouldn’t be unrealistic for the stock to close down between 20% and 25% today. Further declines are likely to come as the bears take charge and the bulls abandon ship!

UPDATE Feb 23, 11:07 – Things don’t seem to be getting any better as DRYS continues the plunge. At the moment, the stock is trading at $2.26 per share after a loss of $0.44 per share or 16.30% thus far today. Considering the momentum, chances are that there is still room to fall!

Never Miss The News Again

Do you want real-time, actionable news delivered to your inbox? Join the CNA Finance mailing list below!

Subscribe Today!

* indicates required










0 419
Alimera Sciences Inc ALIM Stock News

Alimera Sciences Inc (NASDAQ: ALIM)

Alimera Sciences is having an incredibly strong day in the market today. At the opening bell, the stock was trading well into the green before dipping downward back to the break even point in the first few minutes. However, since then, we’ve seen continuous upward movement, driving the stock to impressive gains. Below, we’ll talk about what we’re seeing from ALIM, why, and what we’ll be watching for ahead.





What We’re Seeing From ALIM

As mentioned above, Alimera Sciences is having a great day in today’s trading session. When the session opened for the day, the stock was already trading in the green. Shortly after the open, the stock corrected, falling to the break even point before hitting support and deciding to rocket upward. At the moment (10:47), ALIM is trading at $1.36 per share after a gain of $0.11 per share or 8.48% thus far today.

Why The Stock Is Soaring

As is usually the case, our friends at Trade Ideas were the first to notify us of the upward movement on ALIM. As soon as we got the notification, the CNA Finance team started digging to see exactly why the stock was soaring. It didn’t take long to uncover the story. The gains are the result of news surrounding the FDA.




Early this morning, a press release by the company announced that Health Canada has accepted the company’s New Drug Submission. The submission surrounds ILUVIEN(R) and has been accepted for review. The treatment is designed to treat macular edema in patients who have previously been treated with a course of corticosteroids and did not have a clinically significant rise in intraocular pressure. If approved, the treatment could be overwhelmingly profitable for Alimera Sciences, ultimately, causing exciting among investors.

What We’ll Be Watching For Ahead

Moving forward, the CNA Finance team will be keeping a close eye on ALIM. In particular, we’ll be watching the news surrounding the New Drug Submission and of course, hoping for the best. After all, if it is approved, this treatment could lead to tremendous profits for the company and shareholders alike. Nonetheless, we’ll keep a close eye on the news and continue to bring it to you as it breaks!

Never Miss The News Again

Do you want real-time, actionable news delivered to your inbox? Join the CNA Finance mailing list below!

Subscribe Today!

* indicates required










Internap Corp INAP Stock News

Internap Corp (NASDAQ: INAP)

Internap is having an incredibly strong day in the market today. As soon as the trading session opened, the stock was already trading dramatically in the green. While we did see a bit of a correction shortly after the bell, it didn’t last long, and now, the stock is headed back upward. Below, we’ll talk about what we’re seeing from INAP, why, and what we’ll be watching for ahead.





What We’re Seeing From INAP

As mentioned above, Internap is having an overwhelmingly strong day in the market today. At the opening bell, the stock was already trading on impressive gains. While it did correct a bit since then, the stock found support well ahead of the break even point and is currently headed back upward. At the moment (10:08), INAP is trading at $2.69 per share after a gain of $0.88 per share or 48.61% thus far today.

Why The Stock Is Gaining

As is almost always the case, our partners at Trade Ideas were the first to inform us of the gains on INAP. As soon as we received the notification, the CNA Finance team went to work to see if we could uncover the cause of the movement. In this case, it didn’t take very long. The gains are the result of a fund raising effort that went well.




Internap announced a private placement of about 23.8 million shares early this morning. The shares of common stock sold for a price of $1.81 each, grossing approximately $43 million. The buyers of these shares were a group of investors that includes affiliates of or funds managed by GAMCO Investors as well as accounts advised by Avenir Corporation. In a statement, Peter D. Aquino, President and CEO at INAP had the following to offer…

The confidence demonstrated by our investors in the future of INAP is extremely motivating to the entire management team as we continue our comprehensive operations improvement initiative… The speed with which our new team is moving to right-size our business and invest in sales and marketing to capture strong market demand for Colocation and Cloud Services is impressive. The next steps in the 2017 transformation of the new INAP is to approach the market as two pure plays, complete our debt refinancing, and begin to consider strategic opportunities to bolster organic growth.”

What We’ll Be Watching For Ahead

Moving forward, the CNA Finance team will be keeping a close eye on INAP. In particular, we’ll be watching as the company continues on the restructuring process, toward what we believe will be a far more efficient and profitable endpoint. Nonetheless, we’ll keep a close eye on the progress and continue to bring the updates to you as they break!

Update (11:51): INAP is on a slow, yet steady downward path. At the moment it is trading at $2.28 per share. While that is quite a bit lower than it was at the time of this article’s publication, the gains are still impressive, currently at 25.97, and the stock is still likely to close well in the green.

Never Miss The News Again

Do you want real-time, actionable news delivered to your inbox? Join the CNA Finance mailing list below!

Subscribe Today!

* indicates required










Under Armour Inc Class A UAA Stock News

Under Armour Inc Class A (NYSE: UAA)

Under Armour was off to what seemed like it could have been a rough day in the market today. After starting the day off well into the green, the stock quickly took a dive, making it to the red within the first hour. While it seemed as though all hope was lost for the day, the stock started to spike toward the top minutes ago, quickly making it to the green. Below, we’ll talk about what we’re seeing from UAA, why, and what we’ll be watching for ahead.





What We’re Seeing From UAA

As mentioned above, Under Armour wasn’t having the best of days in the market today. While the stock started the day off in the green, it quickly made a run for the red, making it to the red within the first half hour. However, minutes ago, the stock went from red to green in what seemed like no time at all. Currently (10:14), UAA is trading at $22.07 per share after a gain of $0.29 per share (1.33%) thus far today.

Why The Stock Is Spiking

As is almost always the case, our partners at Trade Ideas were the first to alert us to the gains on UAA. As soon as we received the alert, the CNA Finance team started working to see why the stock was making a run for the top. It didn’t take long to find the reason for the gains. Ultimately, the spike is being caused by a rumor.




At the moment, if you search for Under Armour on your favorite social network, chances are that you will find the rumor too. At the moment, there’s chatter surfacing that the company may be acquired. Now, keep in mind that the rumor is incredibly vague. No one is suggesting who the buyer might be nor at what price.

What We’ll Be Watching For Ahead

Moving forward, the CNA Finance team will be keeping a close eye on UAA. In particular, we’re watching to see if there is any validity to the acquisition rumors happening at the moment. After all, if a takeover does happen, it could return tremendous value to shareholders. We’ll keep a close eye on the news and continue to bring it to you as it breaks!

Never Miss The News Again

Do you want real-time, actionable news delivered to your inbox? Join the CNA Finance mailing list below!

Subscribe Today!

* indicates required










Cemtrex Inc CETX Stock News

Cemtrex Inc (NASDAQ: CETX)

Cemtrex looked like it was going to have a relatively normal day in the market early on. When the opening bell rang, the stock was trading in the green, and throughout about the first 15 minutes, it stayed above the breakeven point. However, minutes ago, the stock started to take a dive. Below, we’ll talk about what we’re seeing from CETX, why, and what we’ll be watching for ahead.





What We’re Seeing From CETX

As mentioned above, Cemtrex seemed to be having a relatively normal start to the trading session today. At the opening bell, the stock was already trading slightly in the green. From there, we saw some upward and some downward movement, but nothing was worth writing home about. That is, until minutes ago when the stock started to spiral downward. Currently (9:53), CETX is trading at $4.71 per share after a loss of $0.41 per share (8.01%) thus far today.

Why The Stock Is Falling

As is almost always the case, our partners at Trade Ideas were the first to inform us of the losses on CETX. As soon as we received the alert, the CNA Finance team started digging to see exactly why the stock was falling. It didn’t take long to uncover the story. At the moment, it seems as though investors are spooked, as allegations have been waged against the company.




We found the allegations via social media, and regardless of which social network is your favorite, you should be able to find them too. All you’ll need to do is search for either “Cemtrex” or “CETX” and the posts should pop up. Unfortunately, any allegations of fraud tend to send stocks sliding out of control, as the allegation is generally the first step toward an investigation and a potentially massive headache for the company.

What We’ll Be Watching For Ahead

Moving forward, the CNA Finance team will be keeping a close eye on CETX. In particular, we’ll be digging deeper into the fraud allegations to see if there is any validity to them. We’ll also be watching the story as it unfolds and working to bring you any new developments as they break!

Never Miss The News Again

Do you want real-time, actionable news delivered to your inbox? Join the CNA Finance mailing list below!

Subscribe Today!

* indicates required










0 339
Cellectar Biosciences Inc CLRB Stock News

Cellectar Biosciences Inc (NASDAQ: CLRB)

While it is early on in the market at the moment, that’s not stopping Cellectar Biosciences from seeing gains. At the open of the trading session, the stock was already trading well in the green. The gains are the result of an announcement surrounding a key Phase 1 clinical trial. Below, we’ll talk about what we’re seeing from the stock, why, and what we’ll be watching for ahead with regard to CLRB.





What We’re Seeing From CLRB

As mentioned above, Cellectar Biosciences is having a relatively strong start to the trading session today. At the open, the stock was already trading well into the green. While we did see some downward movement shortly after the bell, the stock has reached support and is currently headed back upward. At the moment (9:43), CLRB is trading at $2.63 per share after a gain of $0.04 per share or 1.54% thus far today.

Why The Stock Is Headed Up

As is almost always the case, our partners at Trade Ideas were the first to inform us of the upward movement on CLRB. As soon as the CNA Finance team received the alert, we started digging to see exactly what was causing the upward movement. In this particular case, it didn’t take long to dig up the story. The gains are the result of an announcement surrounding a Phase 1 clinical trial.




Early this morning in pre-market hours, Cellectar Biosciences announced that after successfully completing Cohort 3, the company has no initiated its fourth cohort of its Phase 1 clinical trial of CLR 131. In this cohort, patients will receive 31.25 mCi/m2 of CLR 131 as a single dose infusion. This is a 25% increase from cohort 3. The goal of the Phase 1 study is to establish a maximum tolerated single dose of CLR 131. In a statement, Jim Caruso, president and CEO of CLRB, had the following to offer…

Our enthusiasm for CLR 131’s potential in multiple myeloma patients continues to grow given the positive safety, efficacy markers, progression-free survival and median overall survival results that we have observed to date in the Phase 1 trial, particularly given such a heavy pretreated patient population… We will explore the potential enhanced clinical benefits of a two-dose regimen in our imminent Phase II study, and look forward to updating investors on results of the fourth cohort when available.”

What We’ll Be Watching For Ahead

Moving forward, the CNA Finance team will be keeping a close eye on CLRB. In particular, we’ll be paying close attention to continued progression with regard to CLR-131 and we are excited for the coming results of Phase I, Cohort 4. Nonetheless, we’ll be watching the news closely and we will continue to bring it to you as it breaks!

Never Miss The News Again

Do you want real-time, actionable news delivered to your inbox? Join the CNA Finance mailing list below!

Subscribe Today!

* indicates required










0 619
Agenus Inc AGEN Stock News

Agenus Inc (NASDAQ: AGEN)

While the market hasn’t opened quite yet for the day, Agenus isn’t likely to have the best of days. Unfortunately, the stock is falling hard in the pre-market trading hours after announcing that it has stopped patient enrollment into a key study. Below we’ll talk about what we’re seeing from the stock, why, and what we’ll be watching for with regard to AGEN ahead.





What We’re Seeing From AGEN

As mentioned above, the market hasn’t quite opened yet. Nonetheless, in the pre-market, AGEN isn’t having the best of times at the moment. Shortly after information was released with regard to the ceasing of study enrollment, the stock started to dive. At the moment (9:02), AGEN is trading at $4.30 after a loss of $0.24 per share (5.29%) thus far today.

Why The Stock Is Falling

As is almost always the case, our partners at Trade Ideas were the first to notify us of the decliness on AGEN. As soon as the CNA Finance team received the alert, we started digging to see exactly what was causing the movement. In this particular case, it didn’t take long to uncover the story. The declines are ultimately the result of news surrounding a clinical study.




In a regulatory filing that was made available today, investors learned that Agenus has stopped the patient enrollment process for a key Phase 2 clinical study. The study is assessing Prophage G-200 in combination with Avastin as a treatment for patients with surgically resectable recurrent glioblastoma multiforme.

The reason that the enrollment was stopped had to do with an interim analysis. The Data Safety and Monitoring Board suggested that the study was not likely to demonstrate a benefit over bevacizumab alone, and if that’s the case, AGEN is better off cutting its losses rather than continuing.

What We’ll Be Watching For Ahead

Moving forward, the CNA Finance team will be keeping a close eye on AGEN. In particular, we’ll be watching to see if anything changes with regard to the study mentioned above. We’ll also be watching the company’s ongoing work surrounding other treatments in its pipeline. We’ll keep a close eye on the news and continue to bring it to you as it breaks!

Never Miss The News Again

Do you want real-time, actionable news delivered to your inbox? Join the CNA Finance mailing list below!

Subscribe Today!

* indicates required










Thought Leader Discussions

AzurRx BioPharma Inc. AZRX Stock News

0 814
AzurRx BioPharma Inc. (NASDAQ: AZRX) Since first covering AzurRx in December of 2016, many investors have asked me to further expand on the technology and...